Complete financial analysis of Appili Therapeutics Inc. (APLIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Appili Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hui Xian Real Estate Investment Trust (87001.HK) Income Statement Analysis – Financial Results
- American Outdoor Brands, Inc. (AOUT) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. (CRHWF) Income Statement Analysis – Financial Results
- Immobel SA (0NC0.L) Income Statement Analysis – Financial Results
- First Hydrogen Corp. (FHYD.V) Income Statement Analysis – Financial Results
Appili Therapeutics Inc. (APLIF)
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 827.41K | 1.39M | 1.39M | 0.00 | 199.11K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.66K | 6.27K | 0.00 | 14.84K | 0.00 | 20.71K | 17.67K | 10.51K |
| Gross Profit | 813.75K | 1.38M | 1.39M | -14.84K | 199.11K | -20.71K | -17.67K | -10.51K |
| Gross Profit Ratio | 98.35% | 99.55% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.62M | 21.46M | 10.87M | 11.49M | 4.18M | 3.93M | 4.95M | 2.52M |
| General & Administrative | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 2.36M | 1.61M | 1.24M |
| Selling & Marketing | 0.00 | 185.84K | 711.93K | 2.32K | 942.40K | 861.45K | 735.00K | -5.37K |
| SG&A | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 3.22M | 1.61M | 1.24M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 827.41K | 24.95M | 14.37M | 16.28M | 4.37M | 7.14M | 3.77M | 3.76M |
| Cost & Expenses | 8.88M | 24.95M | 14.37M | 16.30M | 4.37M | 7.16M | 3.77M | 3.77M |
| Interest Income | 16.81K | 33.73K | 116.95K | 116.95K | 40.17K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.55M | 69.84K | 69.84K | 12.11K | 0.00 | 208.70K | 0.00 |
| Depreciation & Amortization | 13.66K | 6.27K | 12.64K | 14.84K | 17.75K | 20.71K | 17.67K | 10.51K |
| EBITDA | -2.07M | -7.91M | -24.67M | -15.65M | -5.39M | -6.52M | -6.54M | -3.22M |
| EBITDA Ratio | -249.78% | -1,690.70% | -1,023.99% | 0.00% | -2,185.64% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.05M | -23.52M | -14.26M | -16.30M | -4.37M | -7.16M | -3.77M | -3.77M |
| Operating Income Ratio | -972.94% | -1,691.61% | -1,025.06% | 0.00% | -2,196.05% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.34M | -1.29M | -401.36K | 706.93K | 28.06K | 2.21M | 2.58M | 1.47M |
| Income Before Tax | -3.71M | -25.08M | -14.33M | -14.95M | -4.33M | -4.95M | -3.98M | -2.30M |
| Income Before Tax Ratio | -448.55% | -1,803.42% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.58K | 38.46K | 38.46K | -627.89K | -243.43K | -621.61K | -46.18K | -541.51K |
| Net Income | -3.78M | -25.12M | -14.33M | -14.33M | -4.33M | -4.33M | -3.98M | -1.75M |
| Net Income Ratio | -456.96% | -1,806.18% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| EPS Diluted | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| Weighted Avg Shares Out | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
| Weighted Avg Shares Out (Dil) | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development...
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal...
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today. Results...
Appili Therapeutics Presents at the 10th International Tularemia Conference
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of...
Appili Therapeutics' shares soar on FDA approval for Llikmez oral antibiotic
Appili Therapeutics Inc (TSX-V:APLI) shares rallied after it announced the US Food and Drug Administration (FDA) approved its application for a liquid oral reformulation of the antibiotic metronidazole (ATI-1501). The company's shares were up 45% at C$0.08 by noon in Toronto.
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal...
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief...
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton & Co....
Source: https://incomestatements.info
Category: Stock Reports